ReviewChest2018
Clinical Practice and Infrastructure Review of Fecal Microbiota Transplantation for Clostridium difficile Infection.
Review in Chest, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed.
- Fecal microbiota transplantation in systemic sclerosis: A double-blind, placebo-controlled randomized pilot trial.PloS one · 2020Trial
- Methodological insights into fecal microbiota transplantation: Dissecting key approaches for success.World journal of methodology · 2026Review
- The evolving landscape of live biotherapeutics in the treatment of Clostridioides difficile infection.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2025Review
- Case Report: Oral fecal microbiota transplantation in a Mediterranean spur-thighed tortoise (Frontiers in veterinary science · 2025Article
- Reviewing theMicroorganisms · 2024Review
- Design of 8-mer peptides that block Clostridioides difficile toxin A in intestinal cells.Communications biology · 2023Article
- Pilot evaluation of a single oral fecal microbiota transplantation for canine atopic dermatitis.Scientific reports · 2023Article
- Dysbiome and Its Role in Surgically Relevant Medical Disease.Surgical infections · 2023Review
- Design of 8-mer Peptides that BlockbioRxiv : the preprint server for biology · 2023Article
- Any Future for Faecal Microbiota Transplantation as a Novel Strategy for Gut Microbiota Modulation in Human and Veterinary Medicine?Life (Basel, Switzerland) · 2022Review
- The Regulatory Approach for Faecal Microbiota Transplantation as Treatment forAntibiotics (Basel, Switzerland) · 2022Article
- Successful outcome after a single endoscopic fecal microbiota transplantation in a Shiba dog with non-responsive enteropathy during the treatment with chlorambucil.The Journal of veterinary medical science · 2021Article
- Superiority of Higher-Volume Fresh Feces Compared to Lower-Volume Frozen Feces in Fecal Microbiota Transplantation for Recurrent Clostridioides Difficile Colitis.Digestive diseases and sciences · 2021Article
- Fecal microbiota transplantation for recurrentTherapeutic advances in gastroenterology · 2021Review
- Fecal microbiota transplantation as a new treatment for canine inflammatory bowel disease.Bioscience of microbiota, food and health · 2021Article
- Antibiotics at the crossroads - Do we have any therapeutic alternatives to control the emergence and spread of antimicrobial resistance?Journal of education and health promotion · 2021Review
- Secondary causes of inflammatory bowel diseases.World journal of gastroenterology · 2020Review
- Regulation of Gut Microbiota on Immune Reconstitution in Patients With Acquired Immunodeficiency Syndrome.Frontiers in microbiology · 2020Review
- Impact of Gut Microbiota Composition on Onset and Progression of Chronic Non-Communicable Diseases.Nutrients · 2019Review
- Fecal Microbiota Transplantation: An Update on Clinical Practice.Clinical endoscopy · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
A substantial proportion of Clostridium difficile infection (CDI) cases recur after completion of antibiotic therapy, and antibiotic cure rates diminish with each recurrence of CDI. Fecal microbiota transplantation (FMT) is an effective therapy for recurrent FMT, which otherwise requires prolonged or indefinite antibiotic treatment. FMT is performed by introducing the fecal microbial community obtained from a healthy donor or pool of donors into the stomach, small intestine, or colon of a patient with CDI. Multiple clinical trials support the usefulness of FMT in treating recurrent CDI, and CDI treatment guidelines now include consideration of FMT at the third CDI recurrence. However, there remain challenges to incorporating FMT into clinical practice. First, methods of fecal bacterial community processing vary, as do methods of FMT administration. Second, the optimal dosing strategy and expected benefit of FMT for refractory CDI, particularly for severe and severe complicated cases, are uncertain. Third, the US Food and Drug Administration (FDA) considers FMT an investigational treatment. Fourth, insurance reimbursement for FMT usually falls short of FMT administration costs. In the setting of rising C difficile incidence and growing evidence for FMT efficacy, the demand for FMT has increased. However, uncertainty surrounding optimal FMT preparation and administration methods, FDA oversight, and insurance reimbursement presently limits the clinical practice of FMT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.